Review
Copyright ©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Feb 27, 2018; 10(2): 172-185
Published online Feb 27, 2018. doi: 10.4254/wjh.v10.i2.172
Glycogenic hepatopathy: A narrative review
Jagannath M Sherigar, Joline De Castro, Yong Mei Yin, Debra Guss, Smruti R Mohanty
Jagannath M Sherigar, Joline De Castro, Debra Guss, Smruti R Mohanty, Department of Gastroenterology and Hepatology, NYP-Brooklyn Methodist Hospital, Brooklyn, NY 11215, United States
Yong Mei Yin, NYP-Brooklyn Methodist Hospital, Brooklyn, NY 11215, United States
Author contributions: All authors have equally contributed to this paper with conception and design of the study, literature review, drafting, editing and final approval of the manuscript.
Conflict-of-interest statement: No potential conflicts of interest or financial support related to this paper.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Smruti R Mohanty, MD, MS, FACP, Chief, Department of Gastroenterology and Hepatology, NYP-Brooklyn Methodist Hospital, 5841 S. Maryland Avenue, 506, 6th Street, Brooklyn, NY 11215, United States. srm9006@nyp.org
Telephone: +1-718-7803851 Fax: +1-718-7803478
Received: November 12, 2017
Peer-review started: November 12, 2017
First decision: December 4, 2017
Revised: December 22, 2017
Accepted: January 22, 2018
Article in press: January 24, 2018
Published online: February 27, 2018
Core Tip

Core tip: Glycogenic hepatopathy (GH) is considered as a benign reversible condition. Elevation in transaminases is a common finding in patients with diabetes mellitus, and non-alcoholic fatty liver disease (NAFLD) and GH are the two primary underlying pathologies in most cases. It is essential to distinguish NAFLD from GH as this can progress to advanced liver disease. However, recent studies have identified the varying degree of fibrosis in glycogen hepatopathy as well, further emphasizing the need for future studies. We briefly reviewed the literature on mechanisms involved in the development of GH, evaluation of these patients, recent progress made on diagnostic tests and management.